Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline ...

Australian CEOs are often shy to talk about how and when they use external consultants. The boss of this big French company, ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00. The ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and Cencora ...

Sanofi SA (SNY) stock saw a modest uptick, ending the day at $49.19 which represents a slight increase of $1.04 or 2.16% from the prior close of $48.15. The stock opened at $48.57 and touched a low of ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.